Literature DB >> 7176050

Bilateral renal cell carcinoma: influence of synchronous and asynchronous occurrence on patient survival.

H Zincke, S K Swanson.   

Abstract

Twenty-seven patients with synchronous (19 cases) or asynchronous (8 cases) bilateral renal cell carcinoma were treated and followed for as long as 20 years. Tumor grade and stage generally were more favorable in the former group, which is reflected in the higher surgical intervention rate. Nonsurgical treatment yielded poor results. The 5-year survival rate for patients with synchronous bilateral renal cell carcinoma (77.8 per cent) was significantly higher than that for patients with asynchronous lesions (37.5% per cent). Because of its different presentation and favorable prognosis when treated surgically synchronous bilateral renal cell cancer should be distinguished from the asynchronous form, with its dismal outcome. For the latter cases thorough long-term followup may make early surgical intervention feasible, and thus, improve patient survival.

Entities:  

Mesh:

Year:  1982        PMID: 7176050     DOI: 10.1016/s0022-5347(17)53274-7

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  4 in total

Review 1.  Long-term management of bilateral, multifocal, recurrent renal carcinoma.

Authors:  Gennady Bratslavsky; W Marston Linehan
Journal:  Nat Rev Urol       Date:  2010-05       Impact factor: 14.432

2.  Failed partial nephrectomy: local recurrence vs. multicentric disease.

Authors:  J Cassell; D Dolson; R Linn; Z Wajsman
Journal:  Int Urol Nephrol       Date:  1990       Impact factor: 2.370

3.  Synchronous bilateral multilocular renal cell carcinoma. A rare case.

Authors:  A Kostakopoulos; D Picramenos; P Antonopoulos; N I Stavropoulos
Journal:  Int Urol Nephrol       Date:  1994       Impact factor: 2.370

4.  Bilateral renal cancers: oncological and functional outcomes.

Authors:  Csaba Berczi; Ben Thomas; Zsolt Bacso; Tibor Flasko
Journal:  Int Urol Nephrol       Date:  2016-07-05       Impact factor: 2.370

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.